Coleen Glessner
Responsabile della Conformità presso EMERGENT BIOSOLUTIONS INC.
Patrimonio netto: 1 M $ in data 30/06/2024
Profilo
Coleen Glessner is currently the Executive VP-Quality, Ethics & Compliance at Emergent BioSolutions, Inc. Prior to her current position, she served as the Chief Quality Officer & Senior Vice President at Alexion Pharmaceuticals, Inc. from 2017 to 2021.
Ms. Glessner completed her undergraduate degree at the University of Pittsburgh and holds an MBA from the Massachusetts Institute of Technology.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 08/06/2024 | 163 134 ( 0.31% ) | 1 M $ | 30/06/2024 |
Posizioni attive di Coleen Glessner
| Società | Posizione | Inizio |
|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Responsabile della Conformità | 01/03/2020 |
Precedenti posizioni note di Coleen Glessner
| Società | Posizione | Fine |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2021 |
Formazione di Coleen Glessner
| Massachusetts Institute of Technology | Masters Business Admin |
| University of Pittsburgh | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Coleen Glessner
